Solutions tailored to your pipeline
Global operations, culture and therapeutic expertise aligned to your unique requirements
10+ years of partnership
ICON and Lilly have partnered for more than a decade, in FSP, project sourced studies, and hybrid models. Our work together spans all phases of development, from healthy volunteers, to first in human, through late phase pivotal and observational studies. ICON is dedicated to helping pharmaceutical companies like yours advance their drug development pipelines. The following content highlights areas where our experience, and expertise and solutions align most closely with Lilly's current focus.
Neurodegeneration
Experience in the last five years
-
167
Studies -
4,200+
Sites worldwide -
18,600+
Patients and healthy volunteers
With deep neurodegeneration expertise and innovative technology solutions, ICON offers a unique capacity to design and implement studies with a high probability of success. Our tools reduce the need for site and patient interactions, allowing for greater cost efficiency and increased patient-centricity.
Obesity, diabetes and related complications
Experience in the last five years
-
245
Metabolic disease studies -
6,500+
sites worldwide -
32,800+
Metabolic patients and healthy volunteers

Addressing obesity's impact across the disease spectrum
As global obesity rates rise, the pressure to develop effective and scalable treatments is mounting. Read our latest whitepaper, survey and case study for insights to help guide clinical trial design and drug development strategies to support your pipeline.
We have experience in conducting clinical trials in diabetes and metabolic disorders such as obesity and non-alcoholic steatohepatitis (NASH). Our team can assist in study design, patient recruitment, and data analysis, all of which are critical to the success of these trials.
Oncology and haematologic malignancy
Experience in the last five years
-
47
Oncology drug approvals -
390+
Early phase oncology trials -
516
Solid tumour trials -
275
Oncology and haematologic trials

Advances in imaging biomarkers
Estimating drug efficacy with tumour growth rate modelling
This whitepaper compares the use of imaging biomarker methodologies such as RECIST 1.1 with novel tumour growth rate (TGR) modelling. Using this methodology eliminates the need for a comparable control arm which can reduce research costs. TGR modelling also more efficiently captures heterogeneous tumour measurements and whole-body tumour burden.
Our experts can provide support in various aspects of oncology drug development, including preclinical and clinical trial design, biomarker analysis, and regulatory submission. We have a wealth of experience in immuno-oncology, precision medicine, and combination therapies, which align with your current areas of focus.
Rare disease
Experience in the last five years
-
779
Rare disease studies -
6,200+
Sites worldwide -
24,000+
Patients
We understand the unique challenges rare disease patients face generally and in clinical research studies, compared to those in more common indications. By maintaining focus on the patient, their family, and their quality of life, we can anticipate and mitigate risks, and efficiently conduct rare disease studies.

Accelerated Pharmaceutical Solutions
ICON offers small batch formulation screening and optimisation, analytical method development and validation, stability storage and testing, mock dose & release testing, packaging, labelling, and distribution - including specialised support for oncology drugs and carbon-14 labelled products. Discover out how we can help you achieve faster development timelines, cost savings, and enhanced clinical outcomes.

Flexible delivery models to address your needs
As the world’s leading clinical research organisation powered by healthcare intelligence, and the largest global provider of functional service provision (FSP), ICON is transforming organisational flexibility and operational efficiency.
As clinical trial complexity has increased due to factors such as precision medicine, regulatory requirements, globalisation, and technology use, so have outsourcing models evolved. ICON can deliver full-service, FSP or a blended model that combines the benefits of both, offering flexibility, cost savings, specialised expertise, and greater control over critical aspects of trial operations.

Embracing a blended operating model
Maximising efficiency and flexibility with custom outsourcing
The way the industry outsources is evolving to maximise ROI and efficiency amid increasing complexity and difficulty within the clinical development landscape. The rise of more strategic partnerships and sponsors’ reassessment of their requirements have contributed to the uptick in blended outsourcing models, allowing sponsors to take advantage of best-fit solutions to optimise their programs.
DCT experience and expertise to guide you through the process
Decentralised and hybrid trials bring a range of benefits to the patient and the sponsor. However, every study needs to be assessed for suitability and requires a framework based on a range of different aspects and considerations. ICON can guide you through the choices and provide support to develop a solution that works specifically for your study.
ICON is currently deploying decentralised and hybrid clinical trials on a global basis in multiple therapeutic areas and will support you in navigating the assessment, planning and execution.
FIRECREST digital solutions for greater site engagement
The FIRECREST Site Portal, which is fully customisable to your study, provides single sign-on to a range of education and automation solutions. Connectivity to site and study staff will lead to increased engagement and improved study performance. A flexible enterprise reporting solution offers actionable operational intelligence and management insights on demand, focused on driving value and giving the study team a greater opportunity to detect emerging issues as they happen.
We are excited about the opportunity to partner with Lilly in advancing the development of life-changing therapies.
For more information
We know it requires more action beyond the status quo to support you on your mission to develop and deliver treatments for the most challenging conditions. Contact us for more information and to speak about your specific needs and requirements.
We welcome your input
Our goal is to provide content here that is most useful for your needs. Please take a moment to visit the preference centre and let us know which topics and issues are most important to you.